Singapore, May 22 -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and CellenkosInc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MoU) following the Saudi-US Investment Forum 2025, underscoring KFSHRC's commitment to contributing to the advancement of medical innovation and strengthening strategic global collaborations and Cellenkos' resolve to develop T regulatory (Treg) Cell Therapies for treatment of rare diseases with unmet medical needs.

This landmark MoU establishes the foundation for strategic collaboration between KFSHRC and Cellenkos to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States (US).

The par...